**Author details**

Ravirajsinh N. Jadeja1 , Folami L. Powell1,2 and Pamela M. Martin1,2,3\*

1 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA

2 James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, GA, USA

3 Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA, USA

\*Address all correspondence to: pmmartin@augusta.edu

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**215**

*Repurposing Fumaric Acid Esters to Treat Conditions of Oxidative Stress and Inflammation…*

and Clinical Risk Management.

Opinion. 2014;**30**(2):251-262

2013;**14**(15):2145-2156

[11] Su W, Kansal A, Vicente C,

Deniz B, Sarda S. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Medical Economics. 2016;**19**(7):718-727

[12] Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: Latest developments, evidence and place in therapy. Therapeutic Advances in Chronic Disease. 2016;**7**(4):198-207

[13] Prosperini L, Pontecorvo S.

Dimethyl fumarate in the management of multiple sclerosis: Appropriate patient selection and special considerations. Therapeutics and Clinical Risk Management. 2016;**12**:339-350

[14] Deeks ED. Dimethyl Fumarate: A review in relapsing-remitting MS. Drugs. 2016;**76**(2):243-254

[10] Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, et al. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: A review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opinion on Pharmacotherapy.

[9] Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, et al. BG-12 (dimethyl fumarate): A review of mechanism of action, efficacy, and safety. Current Medical Research and

2014;**10**:229-239

*DOI: http://dx.doi.org/10.5772/intechopen.91915*

[1] Amenta R, Camarda L, Di Stefano V, Lentini F, Venza F. Traditional medicine

as a source of new therapeutic agents against psoriasis. Fitoterapia.

[2] Schweckendiek W. Treatment of psoriasis vulgaris. Medizinische Monatsschrift. 1959;**13**(2):103-104

[3] Roll A, Reich K, Boer A. Use of fumaric acid esters in psoriasis. Indian Journal of Dermatology, Venereology and Leprology. 2007;**73**(2):133-137

[4] Available from: http://www. voteidaneekmiller.com/tag/

[5] Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2009;**7**(7):603-611

[6] Meissner M, Valesky EM,

2012;**10**(11):793-801

2006;**13**(6):604-610

[8] Ruggieri S, Tortorella C,

fumarate - only an anti-psoriatic medication? Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG.

[7] Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. European Journal of Neurology.

Gasperini C. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Therapeutics

Kippenberger S, Kaufmann R. Dimethyl

dimethylfumarate/

2000;**71**(Suppl 1):S13-S20

**References**

*Repurposing Fumaric Acid Esters to Treat Conditions of Oxidative Stress and Inflammation… DOI: http://dx.doi.org/10.5772/intechopen.91915*
